$1.01
-0.98%
N/A-$0.01
Healthcare
Biotechnology
NASDAQ
활발히 거래 중
Propanc Biopharma, Inc. (PPCB) is an Australian biopharmaceutical firm dedicated to developing innovative treatments for various cancers, with a particular focus on ...
Propanc Biopharma, Inc. (PPCB) is an Australian biopharmaceutical firm dedicated to developing innovative treatments for various cancers, with a particular focus on ...
| 날짜 | 임원 | 직책 | 증권 | 구분 | 주식 수 | 가격 |
|---|---|---|---|---|---|---|
| Jul 5, 2023 | ZELINGER JOSEF | director | Common Stock Purchase Warrant | A | 15,000,000 | $0.01 |
| Aug 17, 2021 | Kenyon Julian Norman | director, officer: Chief Scientific Officer | Common stock, par value $0.001 | A | 3,420,000 | — |
| Aug 17, 2021 | Nathanielsz James Andrew | director, officer: CEO/CFO | Common stock, par value $0.001 | A | 5,928,000 | — |
| Aug 17, 2021 | Nathanielsz James Andrew | director, officer: CEO/CFO | Common stock, par value $0.001 | A | 2,800,000 | — |
| Aug 17, 2021 | ZELINGER JOSEF | director | Common stock, par value $0.001 | D | 0 | — |
매수/매도 주식 수와 종가 추세(공통 일간 가격 소스)
X축: 주식 수, 총 주식 수 내림차순
X축: 건수, A+D 건수 내림차순
| 날짜 | 임원 | 직책 | 증권 | 구분 | 주식 수 | 가격 | 금액 |
|---|---|---|---|---|---|---|---|
| Jul 5, 2023 | ZELINGER JOSEF | director | Common Stock Purchase Warrant | A | 15,000,000 | $0.01 | $150,000.00 |
| Aug 17, 2021 | Kenyon Julian Norman | director, officer: Chief Scientific Officer | Common stock, par value $0.001 | A | 3,420,000 | — | — |
| Aug 17, 2021 | Nathanielsz James Andrew | director, officer: CEO/CFO | Common stock, par value $0.001 | A | 5,928,000 | — | — |
| Aug 17, 2021 | Nathanielsz James Andrew | director, officer: CEO/CFO | Common stock, par value $0.001 | A | 2,800,000 | — | — |
| Aug 17, 2021 | ZELINGER JOSEF | director | Common stock, par value $0.001 | D | 0 | — | — |
| Jun 24, 2019 | Campiciano Carlo M | officer | — | — | 0 | — | — |
| May 14, 2019 | Kenyon Julian Norman | director, officer: Chief Scientific Officer | Stock Options (Right to Buy) | A | 9,750,000 | $0.01 | $82,875.00 |
| May 14, 2019 | Kenyon Julian Norman | director, officer: Chief Scientific Officer | Restricted Stock Units | A | 9,750,000 | — | — |
| May 14, 2019 | Nathanielsz James Andrew | director, officer: CEO, Acting CFO, Chairman | Stock Options (Right to Buy) | A | 19,500,000 | $0.01 | $183,300.00 |
| May 14, 2019 | Nathanielsz James Andrew | director, officer: CEO, Acting CFO, Chairman | Restricted Stock Units | A | 19,500,000 | — | — |